Keywords: Janssen, Johnson & Johnson, Nycynta, Zytiga, Neuropathic pain, Prostate cancer, USA, FDA

FDA OKs new indication for Janssen's Nucynta and fast tracks Zytiga sNDA

Article | 30 August 2012

Print This

There were two pieces of good news for US health care giant Johnson & Johnson (NYSE: JNJ) subsidiaries yesterday. First, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in